Statement: All participants in the primary trial are administered with Lapatinib 1500 mg PO QD and Pazopanib 800 mg.
Primary_evidence: INTERVENTION 1:    Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo   Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD). INTERVENTION 2:    Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg   Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD.